Merus B.V.

Merus B.V. focuses on metastatic and recurrent head and neck squamous cell carcinoma, including PD-L1-expressing disease in the first-line setting and disease that has progressed after prior PD-1 and platinum-based therapy.

• Incurable metastatic/recurrent HNSCC
• PD-L1-positive first-line disease
• Post-PD-1 and platinum-treated disease

Research activity in this area centers on petosemtamab alone and in combination with pembrolizumab.